We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

93 hedge funds and large institutions have $139M invested in Dianthus Therapeutics in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 30 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% more ownership

Funds ownership: 5.07% → 5.09% (+0.02%)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

1% less funds holding

Funds holding: 94 → 93 (-1)

34% less capital invested

Capital invested by funds: $211M → $139M (-$72.5M)

37% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 30

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

50% less call options, than puts

Call options by funds: $1K | Put options by funds: $2K

Holders
93
Holders Change
-1
Holders Change %
-1.06%
% of All Funds
1.47%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
15
Increased
19
Reduced
30
Closed
16
Calls
$1K
Puts
$2K
Net Calls
-$1K
Net Calls Change
+$48K

Top Buyers

1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$6.02M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$4.46M
3
Millennium Management
Millennium Management
New York
+$2.46M
4
WP
Woodline Partners
California
+$1.82M
5
DTC
Deep Track Capital
Connecticut
+$1.67M

Top Sellers

1
ACM
Aquilo Capital Management
California
-$14M
2
CC
Casdin Capital
New York
-$3.85M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.54M
4
GGHC
Gilder Gagnon Howe & Co
New York
-$996K
5
Truist Financial
Truist Financial
North Carolina
-$566K
Name Holding Trade Value Shares
Change 		Change in
Stake
TGI
1
TRV GP IV
Massachusetts
$19.6M – – –
DTC
2
Deep Track Capital
Connecticut
$15.5M +$1.67M +30,563 +10%
AVLSA
3
Atlas Venture Life Science Advisors
Massachusetts
$10.1M – – –
GGHC
4
Gilder Gagnon Howe & Co
New York
$9.81M -$996K -18,235 -8%
AI
5
Alphabet Inc
California
$9.68M – – –
CC
6
Casdin Capital
New York
$8.04M -$3.85M -70,507 -29%
O
7
OrbiMed
New York
$6.53M – – –
BlackRock
8
BlackRock
New York
$6.2M -$108K -1,975 -1%
TCM
9
TCG Crossover Management
California
$6.16M -$335K -6,131 -4%
Janus Henderson Group
10
Janus Henderson Group
United Kingdom
$5.53M +$6.02M +110,173 +1,160%
Vanguard Group
11
Vanguard Group
Pennsylvania
$5.39M -$251K -4,595 -4%
Millennium Management
12
Millennium Management
New York
$4.07M +$2.46M +45,013 +105%
Wellington Management Group
13
Wellington Management Group
Massachusetts
$3.79M +$4.46M +81,576 New
GPP
14
Great Point Partners
Connecticut
$3.39M – – –
WP
15
Woodline Partners
California
$2.31M +$1.82M +33,249 +201%
Principal Financial Group
16
Principal Financial Group
Iowa
$1.73M +$3.17K +58 +0.2%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.72M +$141K +2,585 +7%
State Street
18
State Street
Massachusetts
$1.6M -$87.1K -1,595 -4%
BL
19
Bleichroeder LP
New York
$1.41M – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$1.29M +$243K +4,454 +19%
PAI
21
Palo Alto Investors
California
$1.25M – – –
Adage Capital Partners
22
Adage Capital Partners
Massachusetts
$1.13M +$1.32M +24,243 New
Federated Hermes
23
Federated Hermes
Pennsylvania
$1.12M +$458K +8,392 +53%
HMC
24
Harvard Management Company
Massachusetts
$965K – – –
PIM
25
Platinum Investment Management
Australia
$930K – – –
1
2 3 4 5

DNTH Hedge Fund Activity: Q1 2022 in Review

93 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q1 2022, worth a combined $139M — down 34% from $211M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of DNTH and 15 opened new positions — a net loss of 1 holder — while 30 trimmed existing stakes and 19 added.

The largest buyer was Janus Henderson Group, adding an estimated $6.02M. The largest seller was Aquilo Capital Management, exiting entirely with an estimated $14M sold.

  • 93 institutional investors held Dianthus Therapeutics (DNTH) as of Q1 2022, down from 94 in Q4 2021.
  • Funds reported $139M of Dianthus Therapeutics stock for Q1 2022, down 34% quarter-over-quarter.
  • 15 funds opened new Dianthus Therapeutics positions in Q1 2022 and 16 closed out, a net change of -1 holder.
  • The largest Dianthus Therapeutics buyer in Q1 2022 was Janus Henderson Group, an estimated $6.02M added.
  • The largest Dianthus Therapeutics seller in Q1 2022 was Aquilo Capital Management, an estimated $14M sold.

Based on aggregated 13F filings for Q1 2022.